Shell Asset Management’s CareDx CDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-4,805
Closed -$34K 1255
2023
Q3
$34K Sell
4,805
-17
-0.4% -$157 ﹤0.01% 1222
2023
Q2
$41K Sell
4,822
-28
-0.6% -$233 ﹤0.01% 1226
2023
Q1
$44K Sell
4,850
-17
-0.3% -$217 ﹤0.01% 1195
2022
Q4
$56K Sell
4,867
-389
-7% -$5.76K ﹤0.01% 1251
2022
Q3
$89K Sell
5,256
-697
-12% -$15K ﹤0.01% 1264
2022
Q2
$128K Buy
5,953
+3,599
+153% +$99.8K ﹤0.01% 1223
2022
Q1
$87K Sell
2,354
-344
-13% -$13.4K ﹤0.01% 1308
2021
Q4
$123K Buy
2,698
+76
+3% +$3.97K ﹤0.01% 1306
2021
Q3
$166K Sell
2,622
-110
-4% -$8.38K ﹤0.01% 1237
2021
Q2
$250K Buy
2,732
+150
+6% +$11.9K ﹤0.01% 1175
2021
Q1
$176K Buy
+2,582
New +$200K ﹤0.01% 1181

Other funds holding CDNA

Shell Asset Management's CDNA Position: Q4 2023 in Review

Shell Asset Management sold out of CareDx (CDNA) in Q4 2023, closing a stake of 4,805 shares — an estimated $34K sold.

Shell Asset Management first reported a position in CDNA in Q1 2021 and held it in 11 quarters. The position peaked at $250K in Q2 2021. 147 funds tracked by Wall St. Rank hold CDNA as of Q4 2023.

  • Shell Asset Management reported no remaining CareDx position as of Q4 2023 after selling out during the quarter.
  • Shell Asset Management sold 4,805 CareDx shares in Q4 2023, an estimated $34K.
  • Shell Asset Management first reported a position in CareDx in Q1 2021 and held it in 11 quarters.
  • Shell Asset Management's CareDx position peaked at $250K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held CareDx as of Q4 2023.

Based on Shell Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.